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Table 1
Positive and negative ion lipid molecular species identiﬁed by MS/MS
m/z peak Lipid assignment Designation
184.0 Phosphocholine [M+H]+
725.5 SM (d18:1/16:0) [M+Na]+
729.5* SM (d18:1/18:1) [M+H]+
739.5 PC (16:0/18:1-N(CH3)3) [M+K]+
741.5 SM (d18:1/16:0) [M+K]+
750.5* PE (18:0/20:4) [M-H]-
756.5* PC (16:0/16:0) [M+Na]+
767.5 SM (d18:1/19:0) or SM(d18:1/18:1) [M+Na]+ or [M+K]+
790.5* PC (18:0/18:0) [M+H]+
798.5 PC (16:0/18:1) [M+K]+
826.6 PC (18:0/18:1) [M+K]+
853.6 SM (d18:1/24:0) [M+K]+
885.6* PI (C18:0/C20:4) [M-H]-
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branes were sectioned in triplicate in 10 mm thick sections and sub-
sequently washed and digested. Microspots of trypsin were deposited by
means of an automatic chemical inkjet printer with high positional
accuracy. Alpha-Cyano-4-hydroxycinnamic acid matrix (HCCA) was
deposited by a vibrational sprayer system. A Synapt HDMSMALDI-Q-TOF
instrumentwasused to perform the imaging-MSandMS/MSexperiments
with a spatial raster size of 150 mm. Principal Component Analysis (PCA)
and discriminant analysis (DA) were used to build regional molecualr
classiﬁers. A Mascot query was performed after MS/MS experiments for
protein identiﬁcation. The location of tryptic peptideswas visualizedwith
Biomap. Hematoxylin-eosin staining and immunohistochemistry studies
validated and complemented the spatial information.
Results: We have studied the peptide distribution in normal and OA
human synovial tissues by MALDI-MSI. By means of PCA and DA we
distinguished OA and normal tissues based on their tryptic peptide
proﬁles. Tryptic peptides from proteins such as hemoglobin subunit
alpha 2 (m/z 1529.8), hemoglobin subunit beta (m/z 952.5, m/z 1126.6,
m/z 1274.7, m/z 1314.7, m/z 1720.0), actin aortic smooth muscle (m/z
1790.9), biglycan (m/z 1312.8) and ﬁbronectin (m/z 1349.7) have been
identiﬁed, for the ﬁrst time to our knowledge, directly from synovial
membrane biopsies. We have determined the localization of OA related
markers such as the heme group, hemoglobin and ﬁbronectin, all of
them co-localized to inﬂamed areas. Biomap software revealed that the
average intensity for group hemewas higher in OA compared to normal
synovial membrane (0,0110,003 vs. 0,0910,029; p<0.05). Fibro-
nectin immunohistochemistry provided complementary validation of
the results obtained by MALDI-MSI. On the other hand, phosphocoline
(m/z 184) was assigned as a marker of OA tissues but localized in areas
of low inﬂammation. Cluster analyses revealed that peaks assigned to
diacylglycerols and actin were molecular signatures speciﬁc to normal
tissues. Finally, we studied common OA peptides analyzing human
synovial and cartilage tissue sections. We have observed that ﬁbro-
nectin and actin related peptides clearly distinguished the diseased
from the normal tissues. Pathway analyses revealed that ﬁbronectin,
hemoglobin and other OA related proteins interacted with integrin
proteins suggesting that this family of proteins has an important role in
the process of cartilage degradation and synovial inﬂammation.
Conclusions: We have classiﬁed normal and OA human synovial
membranes byMALDI-MSI. Peptides exclusively located in areas of high
inﬂammation were identiﬁed revealing disease speciﬁc proﬁles that
contribute to the understanding of OA affected tissues at the molecular
level.
74
DIFFERENTIAL LIPID PROFILES OF HUMAN MESENCHYMAL STEM
CELLS UNDERGOING CHONDROGENESIS BY MALDI MASS
SPECTROMETRY IMAGING
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Purpose: Recent investigations have argued that there is a close rela-
tionship between altered lipid metabolism and Osteoarthritis (OA)
disease. Mesenchymal stem cells (MSC) are an interesting alternative
for cell-based therapy of cartilage defects due to their capacity to dif-
ferentiate towards chondrocytes in a process called chondrogenesis.
The knowledge of the lipid distribution and modulation during this
process could be used to improve the MSC-based cartilage therapy by
the discovery of new chondrogenic markers. In this study, we have used
matrix-assisted laser desorption/ionization mass spectrometry imaging
(MALDI-MSI) for the characterization of lipids in 3D MSC cultures
(micromasses) at different time points of chondrogenesis.
Methods: MSC micromasses obtained from the bone marrow of 3 OA
donors were collected at day 2 and 14 of chondrogenesis and studied in
duplicate. Samples were cut in sections of 10 mm thickness and dried in
a vacuum desiccator for 20 min to prevent the molecular delocalization.
Two matrix solutions were prepared (Alpha-cyano-4-hydroxycinnamic
acid at 10 mg/ml in 70:30 methanol:triﬂuoroacetic acid 0.2%; 9-Ami-
noacridine at 10 mg/ml in 70:30 ethanol:water) and applied on the
surface of the tissue slides using a vibrational sprayer (ImagePrep,
Bruker, Germany). MALDI-MSI was performed using a MALDI-Q-TOF
instrument (Synapt HDMS, Waters, UK) equipped with a 200-HzNd:YAG laser. Data were acquired in the mass/charge (m/z) range of
100-1000 and at a raster size of 100 mm (positive and negative V-
reﬂectron mode). Ion images were generated with Biomap 3.7.5.5
software. Principal component analysis (PCA) and discriminant analysis
(DA) were used to look for the masses with the highest differences
between all samples studied. Finally, tandem mass spectrometry (MS/
MS) was carried out to identify these masses. Lipid assignments were
performed according to literature and LIPID MAPS Structure Database
(LMSD).
Results: MALDI-MSI revealed a differential lipid proﬁle between the
two time points (2 and 14 days). Firstly, we analyzed the lipid compo-
sition in the positive mode. The analysis of 683 spectra by statistical
methods such as PCA and DA showed a higher lipid content at day 2 of
chondrogenesis. According to Lipidmaps database and MS/MS frag-
mentation, these peaks are attributed to phosphocholine (m/z 184) and
several phosphatidylcholines (PC) (m/z 739.5, m/z 798.5 andm/z 826.6)
(Table 1). Other differentially expressed peaks could be assigned to
sphingomyelines (SM) (m/z 725.5, m/z 741.5, m/z 767.5 and m/z 826.6).
Only m/z 729.5, m/z 756.5 and m/z 790.5 were increased at day 14,
corresponding to SM and two PCs, respectively. For the negative mode
745 spectra were used. The ﬁrst discriminant function revealed a high
presence of phosphatidylinositols (PI) (m/z 885.6) and phosphatidyle-
tanolamines (PE) such as m/z 750.5 speciﬁcally at day 14. Biomap
software conﬁrmed the results obtained by PCA and DA (Figure 1).
Conclusions: These data demonstrate that MALDI-MSI can be used for
the identiﬁcation of putative chondrogenic markers. We have observed
that the lipid metabolism is involved in the chondrogenic process.
Phosphatidyletanolamine and phosphatidylinositol pathways are
increased in chondrocyte-differentiated MSC, whereas phosphocho-
line-related lipids could be markers of the undifferentiated stage.75
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Purpose: All current international clinical guidelines recommend
conservative non-pharmacological treatments, such as physical ther-
apy, for hip osteoarthritis (OA). Physical therapy for hip OA is typically
multimodal, with exercise, manual therapy, education/advice, and gait
aids routinely employed worldwide. While there is limited support for
some individual components, namely exercise and manual therapy,
evidence about the efﬁcacy of physical therapy management is incon-
clusive due to the lack of quality studies. Given the substantial con-
tribution of both the placebo effect and the beneﬁts associated with
therapist contact during OA treatment, inclusion of a sham physical
therapy control group would enable the impact of active physical
therapy to be more accurately evaluated in such trials. Therefore, the
primary aim of this study was to evaluate whether a 12-week multi-
modal physical therapy program, with components typical of interna-
tional clinical practice, leads to greater improvements in pain and
physical function compared to sham physical therapy.
Methods: In a randomized, assessor- and participant-blinded, placebo-
controlled trial, volunteers with hip osteoarthritis were randomly
assigned to receive either active or sham physical therapy. All partic-
ipants received ten treatment sessions over 12 weeks with a physical
therapist. Active treatment comprised a semi-standardized multimodal
program including education/advice, manual therapy, home exercise
and, if appropriate, provision of a gait aid. Sham treatment comprised
inactive ultrasound and application of inert gel to the hip region. During
the 24 weeks following treatment, the active group continued unsu-
pervised home exercise while the sham group self-applied gel three
times weekly. Primary outcomes were average overall pain using a
visual analogue scale (0-100 mm) and physical function (0-68), meas-
ured using the Western Ontario and McMaster Universities Osteo-
arthritis Index (WOMAC) at 13 and 36 following the completion of
treatment. Secondary outcomes assessed physical impairments, phys-
ical performance, psychological status, quality-of-life and cost effec-
tiveness. Statistical analyses were performed on an intention-to-treat
basis using all randomized participants.
Results: One hundred and two participants were enrolled and 96 (94%)
and 83 (81%) completed the week 13 and 36 follow-up measurements
respectively. Baseline characteristics were similar between the two
groups. There were no signiﬁcant between-group differences in change
in VAS pain (48 mm, 95% CI -46 to 143, p¼032) or WOMAC physical
function (07 units, 95% CI -39 to 53, p¼077) at the 13 or 36 week
time points. Observed between-group differences were smaller than
the minimal clinically important differences, and the 95% conﬁdence
intervals indicated that the ranges of plausible between-group differ-
ences were unlikely to have included differences of any practical
importance. Both groups showed signiﬁcant and similar within-group
improvements in pain and physical function at both time points. There
were no between-group differences for changes in all except two sec-
ondary outcomes.
Conclusions: We found that a 12-week multimodal physical therapy







B (CI) P B (CI) P B (CI)
% Weight Change
Continues
1.52 (1.00-2.04) 0.000 1.95 (1.38-2.52) 0.000 1.58 (1.04
% Weight Change
Categories
>10 9.8 (6.3-13.5) 0.000 9.6 (6.1-13.2) 0.000 8.5 (4.5-1
7.6-10 6.6 (2.9-10.3) 0.001 6.1 (2.4-9.7) 0.001 3.8 (0.2-7
5.1-7.5 5.6 (1.9-9.3) 0.003 4.9 (1.3-8.5) 0.007 4.3 (0.7-8
2.5-5 2.5 (-1.3-6.3) 0.205 0.5 (-3.3-4.2) 0.800 0.8 (-3.0-4
<2.5 0 0 0
* Data is presented as regression coefﬁcients (B) with conﬁdence intervals (CI). Change in K
for age, gender, baseline weight, height and KOOS measures.
* Category of weight loss of <2.5 was entered as a reference variable.clinical practice, did not confer additional beneﬁts for hip pain or
function over a realistic sham treatment that controlled for therapist
contact time, therapeutic environment and home treatment. However,
both groups did show signiﬁcant and clinically relevant within-group
improvements following treatment. Given that hip OA patients not
undergoing treatment show little improvements over similar time
frames, the lack of between group differences in our study most likely
reﬂects a large placebo and/or treatment effect from the therapeutic
relationship between the physical therapist and the patient.
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I. Atukorala y, J. Makovey z, L. Lawler x, S. Messier k, K. Bennell{,
D.J. Hunter z. yUniv. of Colombo, Colombo 8, Sri Lanka; zUniv. of Sydney,
Sydney, Australia; x Prima Hlth.Solutions Pty Ltd, Sydney, Australia;
kWake Forest Univ., Winston-Salem, NC, USA; {Univ. of Melbourne,
Melbourne, Australia
Purpose: It has been established that weight reduction has the ability to
decrease pain and disability in knee osteoarthritis (OA). A greater
weight reduction is likely to cause incremental improvement in
symptoms and function by reducing joint loading but has not been
previously investigated. Therefore, this study examined the dose-
response relationship between the magnitude of weight reduction and
improvement in pain and functional outcome.
Methods: Consecutive participants with knee OA enrolled in a weight
loss programme, “Healthy weight for life” were selected. All partic-
ipants fulﬁlled the American College of Rheumatologists criteria for
classiﬁcation of knee osteoarthritis. This program is a structured
remotely delivered 18 week knee and hip OA disease management
program that systematically integrates intensive weight loss as part of
its tailored interventions. This programme was conducted with the aim
of a 7-10% loss of body weight by dietary intervention over 18 weeks.
The participants were provided online and written healthy eating
advice and lifestyle education and tools together with targeted tele-
phone motivation and support. The dietary habits were changed over 3
phases: phase 1 - motivational weight loss utilizing low calorie diet
meal replacement, with controlled portions, and free foods for 6 weeks;
phase 2 - consolidation weight loss for 6 weeks and phase 3 -short term
weight maintenance. All participants in this cohort received the same
strength / balance / mobility exercise tools, instruction, support and
encouragement
All participants were assessed at baseline, 6 weeks and 18 weeks for
body weight and Knee Injury and Osteoarthritis Outcome Score (KOOS).
The dose-response relationship between weight-change category
(>10%, 7.6-10%, 5.1-7.5%, 2.5-5.0% and <2.5% weight loss) and change in
the KOOS scores was assessed using repeated measures ANCOVA and
controlled for baseline age, BMI, baseline KOOS and gender. The weight
loss categories were based on the IDEA trial goal (10%), the weight loss
goal of the diet groups in the ADAPT study (5%) and the weight loss









P B (CI) P B (CI) P
-2.11) 0.11 5.13 (2.45-7.81) 0.000 0.73 (0.51-0.96) 0.000
2.1) 0.000 10.78 (5.2-16.3) 0.000 10.7 (6.5-14.8) 0.000
.5) 0.041 6.6 (0.9-12.3) 0.023 6.6 (2.3-10.8) 0.002
.0) 0.021 6.2 (0.5-11.9) 0.034 7.1 (2.8-11.3) 0.001
.7) 0.667 2.3 (-3.6-8.3) 0.443 4.0 (-0.45-8.4) 0.078
0 0
OOS factors were entered as dependent variables. Regressionmodels were adjusted
